Mainz

• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
• A phase II, multicenter, 1:1 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of bolus applicatio … Recruiting
  2024-511037-35-00 4 2025-01-31 Cyclosporine A is a well known medication and is used to prevent rejec
• A study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythema … Recruiting
  2023-509146-35-00 6 2025-01-30 Systemic Lupus Erythematosus
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• A trial to learn how safe Dato-DXd is when given with osimertinib, and how well it works compared to osimertinib alone in people who have ad … Recruiting
  2023-509883-89-00 5 2025-01-09 Epidermal growth factor receptor (EGFR) mutation-positive, locally adv
• A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-re … Recruiting
  2024-511596-15-00 4 2024-12-26 Liver Diseases, Alcoholic
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k … Recruiting
  2023-510150-17-00 4 2024-12-11 Active, refractory systemic lupus erythematosus (SLE), and active, re
• Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in … Recruiting
  2023-504925-38-00 4 2024-12-10 patients with hormone receptor (HR)-positive, HER2-negative locally ad
• A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc) Recruiting
  2023-510380-34-00 4 2024-12-10 Diffuse cutaneous systemic sclerosis (dcSSc)
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)
• ENhanced recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis after primary Hip Arthroplasty Recruiting
  2023-507490-18-00 5 2024-11-26 Patients undergoing elective unilateral primary hip arthroplasty, who
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma Recruiting
  2024-512113-41-00 5 2024-11-20 Severe Asthma
• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia Recruiting
  2023-505232-36-00 5 2024-11-15 Essential thrombocythemia
• A Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis Recruiting
  2023-508429-29-00 4 2024-09-26 Progressive Pulmonary Fibrosis
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Adaptive Phase 3 Study to Evaluate the Efficacy and Safety of Sinecatechins (De … Recruiting
  2022-502811-12-00 5 2024-09-04 Actinic Keratosis (AK) of the Scalp and/or the Face.
• A study to assess the efficacy and safety of OATD-01 for the treatment of active pulmonary sarcoidosis. Recruiting
  2023-506642-23-01 4 2024-08-28 Active Pulmonary Sarcoidosis
• DICIT: Efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved stable disease as best response in metastat … Recruiting
  2023-504191-26-00 10 2024-08-23 Metastatic Melanoma
• Patient- and care-related benefits of amyloid PET imaging (ENABLE) Recruiting
  2023-503705-10-00 6 2024-08-19 Dementia in Pick disease
• A study to learn how bimekizumab works in children and teenagers with moderate to severe plaque psoriasis Recruiting
  2023-503859-10-00 5 2024-08-12 Moderate to Severe Plaque Psoriasis
• The CLEAN-DUCT / TRITICC-3 trial - Phase IIa, prospective, single arm, open label, non-randomized, multi-center pilot study of durvalumab (M … Recruiting
  2023-509165-21-00 4 2024-08-08 Extrahepatic cholangiocarcinoma (eCCA)
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.

Showing 193–216 of 589 trials